Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes are Two Important Predictors of Drug-induced Liver Injury

Ke Yu, Xingchao Geng, Minjun Chen, Jie Zhang, Bingshun Wang, Katarina ilic and Weida Tong
Drug Metabolism and Disposition January 24, 2014, dmd.113.056267; DOI: https://doi.org/10.1124/dmd.113.056267
Ke Yu
1 National Center for Toxicological Research, US Food and Drug Administration;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xingchao Geng
2 National Institute for the Control of Pharmaceutical and Biological Products, China's State Food and;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minjun Chen
1 National Center for Toxicological Research, US Food and Drug Administration;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jie Zhang
1 National Center for Toxicological Research, US Food and Drug Administration;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bingshun Wang
3 Shanghai Jiao Tong University School of Medicine;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katarina ilic
4 University of Belgrade
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weida Tong
1 National Center for Toxicological Research, US Food and Drug Administration;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: weida.tong@fda.hhs.gov
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Drug-induced liver injury (DILI) is complicated and difficult to predict. It has been observed that drugs with extensive hepatic metabolism have the higher likelihood of causing DILI. Cytochrome P450 (CYP) enzymes are primarily involved in hepatic metabolism. Identifying the associations of DILI with drugs which are CYP substrates, inhibitors, or inducers will be extremely helpful to a clinician in decision-making process when dealing with a patient suspected of having DILI. We collected the metabolism data on CYP enzymes for 254 orally administered drugs in Liver Toxicity Knowledge Base Benchmark Dataset with a known daily dose, and applied logistic regression to identify these associations. We revealed that drugs which are the substrates of CYP enzymes would have the higher likelihood of causing DILI (odds ratio (95% confidence interval) [OR (95% CI)]: 3.99 (2.07-7.67); p < 0.0001), which is dose-independent, and drugs which are the CYP inhibitors would have the higher likelihood of generating DILI only when they are administered at a high daily dose (OR (95% CI): 6.03 (1.32-27.5); p = 0.0098). However, drugs which are the CYP inducers are not observed to be associated with DILI (OR (95% CI): 1.55 (0.65-3.68); p = 0.3246). Our findings will be not only useful to identify suspect medication as a cause of liver injury in clinical settings where the patients are treated with comedications, but also for personalized medicines to understand the individual susceptibility of DILI.

  • cytochrome P450
  • drug induced liver disease
  • drug-induced hepatotoxicity
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Drug Metabolism and Disposition: 51 (6)
Drug Metabolism and Disposition
Vol. 51, Issue 6
1 Jun 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes are Two Important Predictors of Drug-induced Liver Injury
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes are Two Important Predictors of Drug-induced Liver Injury

Ke Yu, Xingchao Geng, Minjun Chen, Jie Zhang, Bingshun Wang, Katarina ilic and Weida Tong
Drug Metabolism and Disposition January 24, 2014, dmd.113.056267; DOI: https://doi.org/10.1124/dmd.113.056267

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes are Two Important Predictors of Drug-induced Liver Injury

Ke Yu, Xingchao Geng, Minjun Chen, Jie Zhang, Bingshun Wang, Katarina ilic and Weida Tong
Drug Metabolism and Disposition January 24, 2014, dmd.113.056267; DOI: https://doi.org/10.1124/dmd.113.056267
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Adipocyte PXR does not play an essential role in obesity.
  • CYP3A-mediated oxidation of DABE and BIBR0951
  • Biodistribution of Lipid in Rats
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics